Idexx Laboratories (IDXX) Cash from Financing Activities (2009 - 2026)

Idexx Laboratories' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$211.4 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 35.99% year-over-year to -$211.4 million; the TTM figure through Mar 2026 stood at -$1.0 billion (up 1.71% YoY), while the FY2025 annual figure was -$1.2 billion, down 32.67% from the prior year.
• Cash from Financing Activities was -$211.4 million for Q1 2026 at Idexx Laboratories, up from -$355.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of -$13.5 million in Q1 2022 to a low of -$355.7 million in Q4 2025.
• Historically, Cash from Financing Activities has averaged -$180.4 million across 5 years, with a median of -$151.0 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities soared 89.6% in 2022, then sank 983.69% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at -$116.7 million in 2022, then rose by 12.75% to -$101.8 million in 2023, then tumbled by 128.57% to -$232.8 million in 2024, then plunged by 52.8% to -$355.7 million in 2025, then soared by 40.56% to -$211.4 million in 2026.
• The last three Cash from Financing Activities figures came in at -$211.4 million (Q1 2026), -$355.7 million (Q4 2025), and -$313.3 million (Q3 2025), per Business Quant data.